Objective: According to the new World Health Organization 2016 classification for tumors of the central nervous system, 1p/19q codeletion defines the genetic hallmark that differentiates oligodendrogliomas from diffuse astrocytomas. The aim of our study was to evaluate whether relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) histogram analysis can stratify survival in adult patients with genetic defined diffuse glioma grades II and III.
D
iffuse gliomas represent most glial neoplasms, with a range of different biological behavior, treatment strategies, and prognoses. The World Health Organization (WHO) classification of gliomas has been extensively redefined in 2016, reflecting certain molecular aberrations that bring important diagnostic and prognostic information. 1, 2 In the updated guidelines, molecular parameters define the brain tumor diagnosis. Diffusely infiltrating gliomas have now been grouped together not only based on the behavioral hierarchy and growth patterns but also on the basis of genetic mutations in the isocitrate dehydrogenase (IDH) 1 and IDH2 genes. 2 The key genotypic feature of an oligodendroglioma, the presence of 1p/19q codeletion, differentiates it from diffuse astrocytoma and is associated with improved radiotherapeutic and chemotherapeutic sensitivity and survival. [3] [4] [5] Histologic grade, although suffering from interobserver and intraobserver variability as well as tissues sampling error, especially in grade II and III tumors [6] [7] [8] [9] is still recognized as an important characteristic for classification of central nervous system tumors. According to the new 2016 WHO classification, diffuse astrocytoma (WHO grade II) and anaplastic astrocytoma (WHO grade III) are now divided in 2 subcategories depending on the mutation of the IDH family of genes (IDH1, IDH2): IDH mutant and IDH wildtype. The diagnosis of oligodendroglioma requires mutation of the IDH gene family in addition to 1p/19q codeletion. 2 Functional imaging techniques like diffusion and perfusion magnetic resonance imaging (MRI) are noninvasive methods capable of assessing water movement and blood flow, respectively. Water diffusion reflects cell density and is measured in terms of apparent diffusion coefficient (ADC). [10] [11] [12] Perfusion MRI is associated with tissue vascularization and most importantly neovascularization in tumor, usually by the relative cerebral blood volume (rCBV). [13] [14] [15] These MRI-based parameters have been used with success to assess not only histologic grade in diffuse gliomas but also for identification of tumors with and without 1p/19q codeletion. [16] [17] [18] [19] [20] [21] [22] In a recent study, Leu et al 23 observed that ADC in combination with rCBV, T2 hyperintense volume, and contrast enhancement allowed them to distinguish between different IDH mutations as well as between IDH mutant with and without 1p/19q codeletion. Furthermore, noninvasive diagnostic alternatives are especially important for repeated monitoring of tumor status and for patients with inoperable tumors.
The purpose of our study was to retrospectively evaluate whether ADC and rCBV histogram analyses can stratify progressionfree survival (PFS) and overall survival (OS) in patients with diffuse gliomas grades II and III with respect to both oligodendroglial and astrocytic tumors.
MATERIALS AND METHODS

Patients
The study was approved by the institutional and regional medical ethics committees, and all patients signed a consent form. A total of 280 consecutive adult patients with a histopathologic diagnosis of diffuse glioma, referred to the regional neurosurgical department between February 2006 and December 2012, were reviewed. Of these, 81 were primary diagnosed as having oligodendrogliomas or astrocytomas according to the status of chromosome 1p/19q (1p/19q codeleted, 1p/19q non-codeleted).
From this cohort, 67 patients (33 women, 34 men; mean age, 47 years; range, 18-82 years) met the inclusion criteria as follows: (1) a baseline preoperative MRI examination from our institution including conventional contrast enhanced T1-weighted images, dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) and diffusion-weighted imaging; (2) minimum 5 years of clinical follow-up; and (3) age greater than 18 years. Patients were excluded for the following reasons: consent not provided (n = 4), incomplete imaging (n = 7), insufficient image quality (n = 2), and previously performed biopsy (n = 1; Fig. 1 ). Patient data on histopathologic and genetic molecular diagnosis, Karnofsky performance status (KPS), comorbidity (diabetes mellitus, cancer, chronic cardiovascular disease, and respiratory disease), and administrated treatments are shown in Table 1 .
Survival Assessments
The initial follow-up MRI scans were obtained 11 to 15 weeks after primary surgery and histologic diagnosis, and then twice yearly the following 5 years. Survival data were registered and assessed using patient records.
Overall survival was defined as the time from diagnosis to death or last follow-up date when the patient was known to be alive. Censoring was performed after 60 months of observation, and May 2017 was the date of administrative censoring. Progression-free survival was defined as the time from diagnosis to tumor progression, recurrence, death, or the last follow-up date in which the patient showed no disease progression. The definition and date of tumor progression were based on the updated Response Assessment in Neuro-Oncology (RANO) criteria. 24, 25 We used 48-month PFS as cutoff to evaluate because several previous studies have reported a median PFS of 27-53 months for patients with diffuse glioma. 26 For further analysis, all patients were divided into 2 groups per OS status: (I) long OS (>60 months) and (II) short OS (<60 months), and into 2 groups per PFS status: (I) long PFS (>48 months) and (II) short PFS (<48 months).
Molecular Genetic Diagnosis
1p19q codeletion status analysis was assessed by polymerase chain reaction by using at least 4 of 6 microsatellite markers on 1p35-36 and 19q13 in the period 2006-2009. 20 The multiplex ligation-dependent probe amplification 27 was used after 2009 in our institution and allows for detecting chromosomal DNA copy number changes of multiple loci simultaneously. Only patients with a defined 1p/19q codeletion status were included in the final analysis and split into 2 groups: (I) gliomas with 1p/19q codeletion, defined as oligodendrogliomas, and (II) gliomas without 1p/19g codeletion defined as astrocytomas.
IDH1 and IDH2 mutations were determined for 55% (37/ intersection gap, 1.5 mm). For each section, 50 images were recorded at intervals equal to the TR. After approximately 8 time points, 0.2 mmol/kg of gadobutrol (Gadovist; Bayer Pharma AG, Berlin, Germany) was injected at a rate of 5 mL/s, immediately followed by a 20-mL bolus of saline (sodium chloride [9 mg/mL]; B. Braun Melsungen, Melsungen, Germany) injected at a rate of 5 mL/s. Postcontrast T1-weighted images were acquired after completion of the dynamic susceptibility-weighted contrast-enhanced MRI (DSC-MRI). 20 
Image Processing
The region of interest outlining the entire tumor volume on ADC maps and T2-weighted images was drawn on each slice by 2 neuroradiologists blinded to histopathologic, genetic/molecular characteristics and clinical outcome (Fig. 2) . The tumor was defined as regions with hyperintensities on T2-weighted images thought to represent pathologic tissue. Areas of contrast enhancement on contrast-enhanced T1-weighted images were always included. Discrepancies were resolved by consensus reading. Care was taken to avoid areas of cysts and nontumoral macroscopic vessels evident on both T2-weighted images (tubular structures with flow void) and on contrast-enhanced T1-weighted images. Relative CBV maps from DSC-MRI were created using established tracer kinetic models, corrected for potential contrast agent leakage from blood-brainbarrier breakdown and normalized to reference tissue. 20 Apparent diffusion coefficient maps from diffusion MRI were created using standard Stejskal-Tanner diffusion approximation. 22, 30 Tumor outlining and processing of ADC and rCBV maps were performed using NordicICE (NordicNeuroLab AS, Bergen, Norway). Whole-tumor normalized histogram distributions of the ADC and rCBV maps were created as described elsewhere. 31 In short, using Matlab 2015 (MathWorks, Natick, MA), 100-bin histogram was created over an ADC range of 0-300 and an rCBV range of 0-7.5 (ratios; arbitrary units), respectively. To correct for varying tumor sizes, the histograms were normalized by making all areas under the histogram curves equal to 1. 20 To reduce the effect of outliers, all ADC and rCBV values below the 5% percentile and over the 95% percentile were excluded.
From this the maximal peak heights of the normalized histogram, rCBV peak and ADC peak were statistically used as measures of vascular and cellular tumor heterogeneity, respectively. 12, 31 In addition, mean ADC (ADC mean ) and mean rCBV (CBV mean ) values of the region of interests were assessed.
Statistical Analysis
Associations between MRI parameters (ADC peak , rCBV peak , ADC mean , rCBV mean ) and patient outcome (PFS and OS) were assessed by using Kaplan-Meier survival analysis and Cox regression with time-dependent covariates. Receiver operating characteristic analysis was used to determine cutoff for dichotomizing the MRI metrics to clinical outcome and used to estimate values of sensitivity, specificity, and area under the curve. A cutoff value for each parameter was determined by maximizing the sum of sensitivity and specificity. Univariate Kaplan-Meier survival analyses were then conducted based on the subgroups obtained from receiver operating characteristic analysis. In addition, KaplanMeier and Cox regression analyses were used to determine whether histopathologic (grades II and III) and molecular genetic status was associated with better outcome. For Cox regression, the following time-dependent covariates were included: KPS, age, comorbidity ("yes" or "no"), character of debut symptoms (epilepsy/ focal neurologic deficit/raised intracranial pressure), primary treatment regime including time and extent of surgical resection (subtotal or gross total resection), type and time of adjuvant therapy (radiation therapy dose of 1.8 Â 30, chemotherapy with temozolomide; MSD Nederland, Oss, the Netherlands) or radiochemotherapy (dose of 1.8 Â 30 Gy with concomitant temozolomide), and time and presence of tumor residuals ("yes" or "no"). For all Cox models, hazard ratios and 95% confidence intervals were estimated. For all cases, a 2-tailed P value of 0.05 or less was considered statistically significant, before potential correction for multiple comparisons by Holm-Bonferroni analysis. Statistical analysis was performed by using SPSS version 18 software (SPSS, Chicago, IL). Table 2 shows the PFS and OS, as well as the values of rCBV peak , rCBV mean , ADC peak , and ADC mean in the prediction of survival outcome in oligodendrogliomas (oligodendroglioma WHO grade II and anaplastic oligodendroglioma WHO grade III) and diffuse astrocytomas (diffuse astrocytoma WHO grade II and anaplastic astrocytoma WHO grade III). The same parameters calculated for the different subgroups are summarized in Table 3 .
RESULTS
Perfusion MRI and PFS/OS
Histogram analysis of DSC-MRI parameters revealed that rCBV peak and rCBV mean were independently associated with PFS in patients with oligodendrogliomas (P < 0.001 and P = 0.003 performed by the Cox regression analysis, where longer PFS [median, 46 vs 37 months] was associated with both higher vascular heterogeneity [lower rCBV peak ] and higher microvascularity [higher rCBV mean ]). In the group with diffuse astrocytomas, longer PFS (median, 37 vs 26 months) was associated with higher rCBV peak , reflecting lower vascular heterogeneity within the tumor. rCBV peak and rCBV mean were also independently associated with PFS in patients with astrocytomas grade III (P = 0.009, P = 0.002).
Histogram analysis of DSC-MRI parameters shows that higher rCBV peak and lower rCBV mean values showed statistically significant longer OS in patients with astrocytomas grade III (medians, 54 vs 37 months [P = 0.004] and 48 vs 23 months [P = 0.008], respectively).
Kaplan-Meier curves of representative prognostic parameters of rCBV peak and rCBV mean are depicted in Figure 2 . Average rCBV histograms (±1.96 SE) for all oligodendrogliomas and diffuse astrocytomas are shown in Figure 3 .
Diffusion MRI and PFS/OS
There was no significant difference in the ADC parameters (ADC peak , ADC mean ) between patients with long and short OS and PFS for neither the oligodendroglioma group nor the astrocytoma group. A combination of rCBVand ADC parameters did not yield a significant survival association. 
Histopathology and PFS/OS
Median PFS and OS for patients with oligodendroglioma grade II are 41 and 58 months; anaplastic oligodendroglioma grade III, 43 and 57 months; diffuse astrocytoma grade II, 35 and 56 months; and anaplastic astrocytoma grade III, 23 and 34 months, respectively. Based on RANO criteria, 38 patients (56%) showed tumor progression by study completion and 18 patients (30%) were deceased at last follow-up.
Survival outcomes for all patients related to diagnosis are shown in Table 4 
DISCUSSION
The present study demonstrates that perfusion MRI parameters derived from rCBV maps analyzed by a histogram method are significant predictors of PFS in patients with diffuse gliomas WHO grades II and III and of OS in patients with astrocytomas grade III. These results emphasize the role of MRI-based microvascular blood volume as an independent prognostic biomarker that may overcome some of the limitations of a histopathologic diagnosis, as well as help guide treatment strategy. In particular, the ability of perfusion MRI to identify lesions associated with poor outcome could select for patients in need of a more aggressive therapeutic strategy and shorter intervals between follow-up examinations.
Patients with diffuse astrocytomas WHO grade II/III and a homogenous distribution of rCBV values (high rCBV peak ) demonstrated longer PFS compared with patients with a heterogeneous distribution (low rCBV peak ). The opposite finding was observed in patients with oligodendrogliomas, where a high rCBV peak and low rCBV mean were associated with shorter PFS. The rCBV histogram analysis was also predictive for OS in patients with astrocytoma grade III, where high rCBV peak and low rCBV mean were associated with better outcome. Conversely, the difference in OS was not significant in patients with diffuse astrocytoma grade II and oligodendrogliomas grade II/III. The most obvious reason for this finding is long survival time among patients of both groups, which is in agreement with previous published studies, where observation time was less than 10 years. [32] [33] [34] For our analysis, we choose 48 months as the cutoff for PFS ("yes/no"), which is in line with median PFS for oligodendrogliomas reported in recently published data. 35 Nevertheless, it may be reasonable to expand the observation time even more, because our material contained a large cohort of patients with grade II gliomas, in which expected median OS could reach 12 to 15 years and beyond.
Interestingly, we identified a more favorable outcome in the group of patients with oligodendroglial tumors with heterogeneous microvascular anatomy (low rCBV peak ) and higher vascularity (high rCBV mean ). These results parallel those of previously published data, suggesting that unlike astrocytic gliomas, high rCBV values do not necessarily indicate aggressive biology associated with poor outcome. 36 The possible biological explanation of a vascular heterogeneous appearance in oligodendrogliomas may be found in the branching network of delicate capillaries typically observed in oligodendrogliomas. 29 In addition, our data suggest that rCBV peak and rCBV mean in oligodendroglial 40 included 12 oligodendroglial tumors in a series of 29 evaluated gliomas and found that normalized maximum rCBV (rCBVmax) may predict 2-year PFS in patients with gliomas, independent of histopathologic findings. In their study, the correlation between rCBVmax and PFS in oligodendroglial tumors was slightly weaker compared with the group with astrocytic tumors only. Jenkinson et al 36 investigated the relationship between rCBV, genotype, and outcome in oligodendroglial tumors and found that rCBV alone was an unreliable indicator for outcome, showing prognostic significance only after stratification for genotype. However, in contrast to our study, all patients included in their study had been treated with chemotherapy.
In contrast to our findings with perfusion MRI, we did not find a significant association between diffusion MRI and survival. These results are in conflict with previous studies where diffusionbased MRI was used to predict survival time. Cuccarini et al 34 demonstrated in a cohort of 89 patients, that significant longer OS was observed in patients with minimum normalized ADC above cutoff ratio of 1.69. Compared to our study both glioma grade I (pilocytic astrocytoma) and grade IV (glioblastoma) were included in their analysis in addition to glioma grades II/III. Moreover, in more recent study, Neill et al 42 observed that median and 90% nADC (histogram metrics of normalized ADC) were significantly associated with PFS in patients with recurrent diffuse glioma grades II and III. In our data, oligodendrogliomas with low ADC peak showed a trend toward longer OS and PFS, but this difference was not significant and any survival association will need to be confirmed in larger, prospective studies.
There is an important difference between the tumor outlining in our study and previous reports. 17, 30, 43 In most reported studies, apparent tumor necrosis was excluded from the region of interest. In contrast, the histogram-based approach, which we used in our analysis, assesses the entire tumor volume. Removing areas of macroscopic necrosis but not regions of micronecrosis beyond visual inspection (ie, below image spatial resolution) is subjective and does not reflect the real tumor heterogeneity. These differences may possibly explain contradictory results with previous published studies, where diffusion-based MRI was used to predict survival time.
There are some limitations in our study that must be considered. First, manual region-of-interest identification is complicated because the diffuse glioma has infiltrating-appearing margin with indistinct borders beyond radiologic visualization. Second, the polymerase chain reaction with microsatellites had been used to assess 1p19q codeletion during the period from 2006 to 2009, which is considered less sensitive than multiplex ligationdependent probe amplification analysis that has been used in our institution since 2009. Finally, IDH1 and IDH2 mutations were determined in only 55% of patients; however, the IDH mutation rate in 1p/19q codeleted tumors is close to 100%. 29, 44, 45 In conclusion, our results indicate that perfusion MRI provides sensitive prognostic markers for OS and PFS in patients with diffuse gliomas and might serve as an independent factor to predict prognosis. Thus, imaging-based biomarkers of vascularity may therefore constitute as a noninvasive supplement to histopathologic and molecular genetic markers and provide important information to guide treatment.
